Welcome to our dedicated page for KalVista Pharmaceuticals SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KalVista Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KalVista Pharmaceuticals's regulatory disclosures and financial reporting.
KalVista Pharmaceuticals, Inc. is the subject of an amended Schedule 13G/A in which a group of Venrock-affiliated investment entities and two individuals report their current holdings. As of June 30, 2026, each reporting person discloses beneficial ownership of 0 shares of KalVista common stock, representing 0.0% of the class.
The filing states that the group has no sole or shared power to vote or dispose of any KalVista shares, confirming ownership of 5 percent or less of the common stock. Multiple Venrock entities and individuals Nimish Shah and Bong Y. Koh are identified as the reporting persons, with powers of attorney and a joint filing agreement referenced in the exhibits.
KalVista Pharmaceuticals, Inc. received an updated Schedule 13G/A (Amendment No. 5) from Tang Capital entities and Kevin Tang regarding ownership of KalVista common stock (CUSIP 483497103).
The filing states that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. each beneficially own 0 shares of KalVista common stock, representing 0% of the class. The filing also reports 0 shares for sole or shared voting power and for sole or shared dispositive power, and confirms that these reporting persons now hold ownership of 5 percent or less of this class of securities.
KalVista Pharmaceuticals, Inc. received an ownership update from SilverArc Capital Management, LLC and Devesh Gandhi. The reporting persons state they now beneficially own 0 shares of the company’s Class A Common Stock, representing 0% of the class. They report no sole or shared voting or dispositive power over any shares and indicate that they are owners of 5 percent or less of this class of securities.
KalVista Pharmaceuticals, Inc. is reported as having no beneficial ownership by SilverArc Capital Management, LLC and Devesh Gandhi. The reporting persons state they beneficially own 0 shares of KalVista Class A Common Stock and 0% of the class, with no sole or shared voting or dispositive power over any shares. The filing is made to indicate ownership of 5 percent or less of this class of securities.
KalVista Pharmaceuticals has been acquired by Chiesi Group and is being taken private. Chiesi completed a tender offer for all KalVista common shares at $27.00 in cash per share, with approximately 43,152,532 shares, or 77.8% of outstanding shares, validly tendered.
After the tender offer, a short-form merger under Delaware law was completed, converting all remaining shares into the right to receive the same cash price and making KalVista a wholly owned Chiesi subsidiary. KalVista’s stock has ceased trading on the Nasdaq Global Market, and the company plans to deregister its shares and suspend SEC reporting.
The filing also details updated terms for KalVista’s 3.250% Convertible Senior Notes due 2031, which are now convertible into $1,606.28 in cash per $1,000 principal amount, executive transaction bonuses, a tax gross-up agreement for the CFO, termination of equity plans, and a full board change with Chiesi’s designee becoming sole director.
KalVista Pharmaceuticals director Nancy Stuart reported the disposition of stock options in connection with the company’s acquisition by Chiesi Farmaceutici. A Chiesi subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary.
Under the merger terms, each outstanding KalVista stock option with an exercise price below $27.00 became fully vested, was cancelled, and converted into a right to receive cash equal to the in-the-money value multiplied by the number of option shares. Any option with an exercise price at or above $27.00 was cancelled with no payment. After these transactions, the filing shows no remaining derivative positions for Stuart.
KalVista Pharmaceuticals director Brian JG Pereira reported the disposition of stock options in connection with the company’s merger with Chiesi Farmaceutici. On June 11, 2026, he surrendered multiple fully vested options covering a total of 91,000 shares of common stock to the issuer.
Under the Agreement and Plan of Merger, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary. Options with exercise prices below $27.00 were cancelled and converted into cash rights based on the spread between the merger price and each option’s exercise price, while any options with exercise prices equal to or above $27.00 were cancelled for no consideration.
KalVista Pharmaceuticals director William Fairey reported the disposition to the issuer of three stock option awards in connection with the company’s merger with Chiesi Farmaceutici. On June 11, 2026, options covering 30,000, 10,000, and 17,000 shares of common stock were cancelled, leaving no remaining options from these grants.
Under the Merger Agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, followed by a merger that made KalVista a wholly owned subsidiary. Each in-the-money option automatically vested and was converted into a cash right based on the difference between the $27.00 Merger Consideration and the option’s exercise price, while any options with exercise prices at or above $27.00 were cancelled for no payment.